Which outcomes should be used in future bronchiolitis trials? Developing a bronchiolitis core outcome set using a systematic review, Delphi survey and a consensus workshop.
bronchiolitis
core outcome sets
paediatrics
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
09 03 2022
09 03 2022
Historique:
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
28
4
2022
Statut:
epublish
Résumé
The objective of this study was to develop a core outcome set (COS) for use in future clinical trials in bronchiolitis. We wanted to find out which outcomes are important to healthcare professionals (HCPs) and to parents and which outcomes should be prioritised for use in future clinical trials. The study used a systematic review, workshops and interviews, a Delphi survey and a final consensus workshop. Thirteen parents and 45 HCPs took part in 5 workshops; 15 other parents were also separately interviewed. Fifty-six items were identified from the systematic review, workshops and interviews. Rounds one and two of the Delphi survey involved 299 and 194 participants, respectively. Sixteen outcomes met the criteria for inclusion within the COS. The consensus meeting was attended by 10 participants, with representation from all three stakeholder groups. Nine outcomes were added, totalling 25 outcomes to be included in the COS. We have developed the first parent and HCP consensus on a COS for bronchiolitis in a hospital setting. The use of this COS will ensure outcomes in future bronchiolitis trials are important and relevant, and will enable the trial results to be compared and combined. ISRCTN75766048.
Identifiants
pubmed: 35264343
pii: bmjopen-2021-052943
doi: 10.1136/bmjopen-2021-052943
pmc: PMC8915376
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e052943Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: The authors declare that they have no competing interests.
Références
N Engl J Med. 2015 Nov 19;373(21):2048-58
pubmed: 26580997
Trials. 2012 Aug 06;13:132
pubmed: 22867278
Thorax. 2005 Dec;60(12):1035-8
pubmed: 16143582
BMC Med. 2011 Jul 21;9:89
pubmed: 21777435
Lancet. 2017 Mar 4;389(10072):930-939
pubmed: 28161016
BMJ Open. 2015 Sep 18;5(9):e008522
pubmed: 26384724
Trials. 2018 Nov 14;19(1):627
pubmed: 30428935
N Engl J Med. 2000 Jun 22;342(25):1907-9
pubmed: 10861329
J Pediatr. 2019 Dec;215:199-208.e8
pubmed: 31570155
Qual Life Res. 2014 Nov;23(9):2495-504
pubmed: 24817317
Trials. 2017 Jun 20;18(Suppl 3):280
pubmed: 28681707
N Engl J Med. 2014 Aug 21;371(8):711-22
pubmed: 25140957
BMJ. 2010 Feb 15;340:c365
pubmed: 20156912
Midwifery. 2014 Dec;30(12):1147-8
pubmed: 25434973
Pediatrics. 2017 Dec;140(6):
pubmed: 29184035
Lancet. 2017 Jan 14;389(10065):211-224
pubmed: 27549684
BJOG. 2014 Sep;121(10):1188-94; discussion 1195-6
pubmed: 24571433
N Engl J Med. 2018 Mar 22;378(12):1121-1131
pubmed: 29562151
PLoS Med. 2016 Oct 18;13(10):e1002148
pubmed: 27755541
BMJ. 2015 Jun 02;350:h2305
pubmed: 26037525
Evid Based Child Health. 2014 Sep;9(3):733-47
pubmed: 25236311
J Clin Epidemiol. 2019 Apr;108:110-120
pubmed: 30557677
PLoS One. 2014 Feb 26;9(2):e89186
pubmed: 24586581
Evid Rep Technol Assess (Summ). 2003 Jan;(69):1-5
pubmed: 12624885
Eur J Clin Pharmacol. 2011 May;67 Suppl 1:49-59
pubmed: 21104409
Arch Dis Child. 2003 Dec;88(12):1065-9
pubmed: 14670770
JAMA Intern Med. 2013 Jun 10;173(11):972-9
pubmed: 23699837
Trials. 2013 Mar 12;14:70
pubmed: 23497540
BMJ Paediatr Open. 2020 Oct 27;4(1):e000780
pubmed: 33134562
Eur J Pediatr. 2019 Feb;178(2):131-138
pubmed: 30610420
BMJ Open. 2014 May 15;4(5):e005045
pubmed: 24833694